Gilead Sciences Inc.’s (GILD) Trodelvy, which is under priority review by the FDA, for an expanded indication, awaits the FDA decision in February. This time, Trodelvy is proposed for the treatment of adult patients with unresectable locally advanced or metastatic HR+/HER2-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. The drug is already approved in the U.S. for the treatment of metastatic triple-negative breast cancer (mTNBC) and metastatic urothelial cancer (mUC). Trodelvy is approved in more than 35 countries. For the first nine months of 2022, the drug generated sales of $485 million, up from $262 million in the year-ago period.GILD closed Friday’s trading at $83.73, up 0.13%.